

# IMMUNE-MEDIATED TREATMENT IN HEAD AND NECK CANCER: TRANSFORMING CARE?

**TUESDAY, APRIL 25, 2017**

**REGISTRATION, DINNER AND REFRESHMENTS: 5:45 PM – 6:00 PM**

**PROGRAM: 6:00 PM – 7:15 PM**

**VENUE: MANCHESTER GRAND HYATT, 1 MARKET PLACE, SAN DIEGO, CA**

**ROOM: GASLAMP A-D**

*The recent approval of immune checkpoint inhibitors and the fast-paced development of emerging therapies have had a major impact on the management of head and neck cancer. This program will zero in on what clinicians need to know about these therapies, how to integrate them into practice, and what to expect in the near future.*



***Barbara A. Burtness, MD***

Professor of Medicine  
Disease Aligned Research Team Leader  
Head and Neck Cancers Program  
Co-Director  
Developmental Therapeutics Research Program  
Yale University School of Medicine  
New Haven, Connecticut



***Robert I. Haddad, MD***

Disease Center Leader  
Head and Neck Oncology Program  
Dana Farber Cancer Institute  
Boston, Massachusetts

**Medscape**  
**EDUCATION**

Supported by an independent educational grant from  
AstraZeneca Pharmaceuticals LP

*To register, please visit:*

**[www.medscape.org/townhall/headandneckcancer-registration](http://www.medscape.org/townhall/headandneckcancer-registration)**

## PROGRAM AGENDA

**5:45 PM – 6:00 PM**

**Registration, Dinner and Refreshments**

**6:00 PM – 6:10 PM**

**Welcome and Introduction**

Barbara A. Burtness, MD

**6:10 PM – 6:30 PM**

**Overview**

Barbara A. Burtness, MD, and  
Robert I. Haddad, MD

**6:30 PM – 6:50 PM**

**Treatment Algorithm Today:**

**Use of PD-1 Inhibitors in HNSCC**

Robert I. Haddad, MD

**6:50 PM – 7:10 PM**

**Moving Beyond Today**

Barbara A. Burtness, MD

**7:10 PM – 7:15 PM**

**Conclusion and Q&A**

Barbara A. Burtness, MD, and  
Robert I. Haddad, MD

## TARGET AUDIENCE

This activity is intended for oncologists, otolaryngologists, and other healthcare providers treating patients with head and neck cancer.

## GOAL STATEMENT

The goal of this program is to improve oncologists' and head and neck specialists' understanding of the emerging role of immunotherapy in the treatment of patients with advanced head and neck squamous cell cancer.

## LEARNING OBJECTIVES

Upon completion of this activity, participants will:

- Have increased knowledge regarding emerging clinical trial data on the management of recurrent or metastatic head and neck cancer
- Demonstrate greater competence related to selecting the most appropriate regimen for a patient with recurrent or metastatic head and neck cancer

## ACCREDITATION STATEMENT

**Medscape** Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

### Physicians

Medscape, LLC designates this live activity for a maximum of 1.25 **AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Medscape**  
EDUCATION  
825 Eighth Avenue  
11th Floor  
New York, NY 10019  
212-301-6700

